Hematology Clinical Trial Report - prIME Oncology
Virtual Poster
Virtual Poster

Hematology Clinical Trial Report

Putting Key Findings From the 2018 Hematology Annual Meeting Into Practice

Not a member of My prIME? Join now for instant access.

View CME-certified virtual poster presentations and downloadable slides covering the most up-to-date clinical trial data from the 2018 Hematology Annual Meeting in San Diego.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.75 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Apr 15, 2019

Expiration Date

Apr 15, 2020

AML

Richard F. Schlenk, MD

Abstract #81: Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia (AML): Results from the prospective randomized AMLSG 09-09 phase-III study

Featured Expert: Richard F. Schlenk, MD

Michael J. Absalon, MD, PhD

Abstract #336: A phase I/pilot study of CPX-351 [daunorubicin and cytarabine liposome for injection (Vyxeos®)] for children, adolescents and young adults with recurrent or refractory

Featured Expert: Michael J. Absalon, MD, PhD

Naval G. Daver, MD

Abstract #27: A phase I, first-in-human study evaluating the safety and preliminary antileukemia activity of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia and other CD123-positive hematologic malignancies

Featured Expert: Naval G. Daver, MD

Eytan M. Stein, MD

Abstract #560: Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions

Featured Expert: Eytan M. Stein, MD

Jorge Cortes, MD

Abstract #26: Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia

Featured Expert: Jorge Cortes, MD

Treatment Complications

Paul Richardson, MD

Abstract #815: A pooled analysis of survival by defibrotide timing of initiation in adults with veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) following hematopoietic stem cell transplant (HSCT)

Featured Expert: Paul Richardson, MD

Yi-Bin Chen, MD

Abstract #605: A phase 1b study of intravenous vedolizumab plus standard of care for graft-versus-host disease prophylaxis in subjects undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies: 6-month results

Featured Expert: Yi-Bin Chen, MD

Yi-Bin Chen, MD

Abstract #601: Results from REACH1, a single-arm phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease

Featured Expert: Yi-Bin Chen, MD

Shernan G. Holtan, MD

Abstract #71: Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Featured Expert: Shernan G. Holtan, MD

  • Michael J. Absalon, MD, PhDCincinnati Children's Hospital Medical Center
    Cincinnati, Ohio, United States
  • Yi-Bin Chen, MDMassachusetts General Hospital
    Boston, Massachusetts, United States
  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Naval G. Daver, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Shernan G. Holtan, MDUniversity of Minnesota
    Minneapolis, Minnesota, United States
  • Paul Richardson, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Richard F. Schlenk, MDNational Center of Tumor Diseases Heidelberg
    Heidelberg, Germany
  • Eytan M. Stein, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States

This educational activity is specifically designed to meet the needs of practicing hematologists, oncologist/hematologists, oncology nurses, researchers and other health care professionals involved and/or interested in the therapeutic management of patients with blood related cancers and the consequences of this disease.

After successful completion of this educational activity, participants should be able to:

  • Identify clinical trial data presented at 2018 Hematology Annual Meeting in San Diego
  • Incorporate new findings presented in San Diego into patient treatment regimens, where applicable

This educational activity is supported by grants from Jazz Pharmaceuticals and ImmunoGen.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1.75 hours

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Absalon has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Chen has disclosed that he has received consulting fees from Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cortes has disclosed that he has received consulting fees from Astellas, Daiichi-Sankyo, Novartis, and Pfizer. He has performed contracted research for Astellas, Daiichi-Sankyo, Immunogen, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Daver has disclosed that he has received consulting fees from Agios; Astellas; Bristol-Myers Squibb; Celgene Corporation; Daiichi-Sankyo; Incyte; Jazz Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd.; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Holtan has disclosed that she has received consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Incyte, and Janssen. She has also performed contracted research for Incyte. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Richardson has disclosed that he has received consulting fees from Jazz Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schlenk has disclosed that he has received consulting fees and research funding from Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Stein has disclosed that he has received consulting fees for membership on advisory boards from Agios; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Novartis Oncology; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
  • Heather Tomlinson, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Clovis Oncology; F. Hoffmann-La Roche Ltd; ImmunoGen; Merck KGaA, Darmstadt, Germany; Pfizer; Novartis Oncology; Puma Biotechnology; and Tesaro

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.